These findings, if taken together with the effect that niclosamide shows in inhibiting the ERK/MAPK pathway and its attending inflammation, can suggest the possibility of this drug having a potential efficacy in tackling ERK-induced mitochondrial dysfunction and the associated oxidative stress, which can support its usefulness in CNS disorders, and provide a basis for repurposing it towards autism spectrum disorders. This evidence concerns the gene MAPK1 and autism spectrum disorder.